Elizabeth Ditty

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Jeremy R. Duvall, M. Protopopova, S. Collins, 2022, Cancer Research.

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Jeremy R. Duvall, M. Protopopova, S. Collins, 2021, Immunology.

Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer

Steven P. Bradley, S. Collins, Phonphimon Wongthida, 2021, Experimental and Molecular Therapeutics.

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Jeremy R. Duvall, S. Collins, Phonphimon Wongthida, 2023, Molecular cancer therapeutics.